Anaplastic lymphoma kinase (ALK) gene alteration in gastric signet ring cell carcinoma

Cancer Biomark. 2016 Mar 11;16(4):569-74. doi: 10.3233/CBM-160599.

Abstract

Background: This study was aimed to investigating the frequency of Anaplastic lymphoma kinase (ALK) alterations in patients with gastric signet ring cell carcinoma (SRC) and the correlations between ALK alterations and the clinical-pathological features.

Methods: The expression of ALK protein was first determined in paraffin-embedded tissue specimens (FFPE) from 177 pathologically confirmed SRC patients by Ventana Immunohistochemistry (IHC). Then patients with ALK positive detected by IHC were assayed in ALK rearrangement by Fluorescence in Situ Hybridization (FISH).

Results: We assessed 4 of 177 cases (2.3%) as positive by IHC. 3 of the 4 patients had T4 tumors and positive nodal status, and 1 of them had metastasis. All of them were HER2 negative. All of the 4 patients were positive for ALK rearrangement using the standard criteria of FISH.

Couclusion: Our analysis showed that about 2.3% of Chineses SRC patients treated in our hospital were ALK positive. Ventana IHC and FISH were both of the reliable approaches in SRC patients. Patients with ALK positive seemed to have deep infiltrated and positive lymph nodes and HER2 negative.

Keywords: Anaplastic lymphoma kinase (ALK); gastric cancer; signet ring cell carcinoma (SRC).

MeSH terms

  • Adult
  • Aged
  • Anaplastic Lymphoma Kinase
  • Biomarkers, Tumor
  • Carcinoma, Signet Ring Cell / genetics*
  • Carcinoma, Signet Ring Cell / pathology
  • Female
  • Gene Expression
  • Gene Rearrangement
  • Genetic Variation*
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases